Formycon AG
Formycon AG (0W4N.L) Financial Performance & Income Statement Overview
Review Formycon AG (0W4N.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Formycon AG (0W4N.L) Income Statement & Financial Overview
Review Formycon AG 0W4N.L income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $42.78M | $26.89M | $33.91M | $43.79M |
| Cost of Revenue | $29.86M | $24.98M | $28.24M | $26.15M |
| Gross Profit | $12.93M | $1.91M | $5.67M | $17.64M |
| Gross Profit Ratio | $0.30 | $0.07 | $0.17 | $0.40 |
| R&D Expenses | $6.81M | $9.69M | $3.99M | $5.17M |
| SG&A Expenses | $11.41M | $9.90M | $8.59M | $5.98M |
| Operating Expenses | $18.22M | $19.89M | $12.58M | $11.15M |
| Total Costs & Expenses | -$48.08M | $44.88M | $40.82M | $37.30M |
| Interest Income | $2.83M | $767000.00 | $2.43M | $386000.00 |
| Interest Expense | $808000.00 | $299000.00 | $50000.00 | $46000.00 |
| Depreciation & Amortization | $8.73M | $472000.00 | $983000.00 | $904000.00 |
| EBITDA | -$97.09M | -$17.52M | $64.88M | $16.18M |
| EBITDA Ratio | -$2.27 | -$0.65 | -$0.17 | $0.17 |
| Operating Income | -$5.30M | -$17.98M | -$6.91M | $6.49M |
| Operating Income Ratio | -$0.12 | -$0.67 | -$0.20 | $0.15 |
| Other Income/Expenses (Net) | -$101.33M | -$4.47M | $70.76M | $2.58M |
| Income Before Tax | -$106.62M | -$22.46M | $63.84M | $15.22M |
| Income Before Tax Ratio | -$2.49 | -$0.84 | $1.88 | $0.35 |
| Income Tax Expense | -$20.98M | $2.40M | -$3.98M | $7.26M |
| Net Income | -$115.58M | -$10.09M | $73.99M | $1.80M |
| Net Income Ratio | -$2.70 | -$0.38 | $2.18 | $0.04 |
| EPS | -$6.54 | -$0.58 | $4.61 | $0.11 |
| Diluted EPS | -$6.54 | -$0.58 | $4.61 | $0.11 |
| Weighted Avg Shares Outstanding | $17.66M | $17.29M | $16.04M | $15.83M |
| Weighted Avg Shares Outstanding (Diluted) | $17.66M | $17.29M | $16.04M | $15.96M |
Over the past four quarters, Formycon AG demonstrated steady revenue growth, increasing from $43.79M in Q2 2023 to $42.78M in Q4 2024. Operating income reached -$5.30M in Q4 2024, maintaining a consistent -12% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$97.09M, reflecting operational efficiency. Net income dropped to -$115.58M, with EPS at -$6.54. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan